With the latest layoffs, Novartis expects to let go of around 800 employees by the end of 2028. More than half of the cuts ...
Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, ...
A few short days after announcing an FDA pivot on a separate asset, REGENXBIO is planning to test the agency’s apparent ...
Patients treated with Bristol Myers Squibb’s Krazati in combination with cetuximab saw shorter median overall and progression-free survival than comparators on chemotherapy. Bristol Myers Squibb’s RAS ...
After 27 deaths were reported in a group receiving its blood cancer drug, ADC Therapeutics is downsizing, implementing ...
The mid-stage disappointment in Alzheimer’s disease delivers another blow to Neuphoria Therapeutics, which in November last year was forced to launch a strategic business review after a Phase 3 trial ...
Speaking to media on Tuesday, BIO CEO John Crowley complimented China’s rise as a biotech powerhouse but said U.S. policy ...
Jubilant HollisterStier received a warning letter over problems that the FDA said necessitate an immediate and comprehensive ...
Many of the FDA’s decisions this quarter involve applications that have previously been delayed, declined or outright ...
The approval of Ionis Pharmaceuticals’ Tryngolza for severe hypertriglyceridemia could spur “substantial growth” for the ...
Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals is the largest pickup in the company’s history, according to analysts at BMO Capital Markets. Vertex Pharmaceuticals is absorbing ...
Sarepta Therapeutics is seeking to convert the accelerated approval of its therapeutic exon-skippers for Duchenne muscular dystrophy to full despite the drugs’ failure to improve motor function in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results